Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Clin Trials. 2019 Jan 28;16(2):165–175. doi: 10.1177/1740774518824539

Table 2:

Statistical hypotheses for the Phase III PROSPECT trial (N1048)

Disease-Free Survival Time to Local Recurrence
Hazard ratio comparing intervention to standard treatment groups: ≥1.23 ≥1.775
Based on design assumption corresponds to: A 3-year DFS rate in the intervention group of 69% versus 74% in the standard group. A 3-year local recurrence free rate of 93% in intervention versus 96% in the standard group.